Biogen
BIIB
1,084 hedge funds and large institutions have $40.6B invested in Biogen in 2019 Q1 according to their latest regulatory filings, with 119 funds opening new positions, 389 increasing their positions, 437 reducing their positions, and 164 closing their positions.
0.4% more ownership
Funds ownership: 87.24% → 87.63% (+0.4%)
5% less funds holding
Funds holding: 1,140 → 1,084 (-56)
10% less call options, than puts
Call options by funds: $1.15B | Put options by funds: $1.28B
11% less repeat investments, than reductions
Existing positions increased: 389 | Existing positions reduced: 437
22% less capital invested
Capital invested by funds: $52.2B → $40.6B (-$11.6B)
24% less funds holding in top 10
Funds holding in top 10: 29 → 22 (-7)
27% less first-time investments, than exits
New positions opened: 119 | Existing positions closed: 164
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$335M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$279M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$275M |
| 4 |
Boston Partners
Boston,
Massachusetts
|
+$235M |
| 5 |
D.E. Shaw & Co
New York
|
+$205M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$509M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$352M |
| 3 |
JP Morgan Chase
New York
|
-$277M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$256M |
| 5 |
O
OrbiMed
New York
|
-$235M |
BIIB Hedge Fund Activity: Q1 2019 in Review
1,084 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2019, worth a combined $40.6B — down 22% from $52.2B a quarter earlier.
Sellers outnumbered buyers: 164 funds closed out of BIIB and 119 opened new positions — a net loss of 45 holders — while 437 trimmed existing stakes and 389 added.
The largest buyer was AQR Capital Management, adding an estimated $335M. The largest seller was Ameriprise, cutting an estimated $509M.
- 1,084 institutional investors held Biogen (BIIB) as of Q1 2019, down from 1,140 in Q4 2018.
- Funds reported $40.6B of Biogen stock for Q1 2019, down 22% quarter-over-quarter.
- 119 funds opened new Biogen positions in Q1 2019 and 164 closed out, a net change of -45 holders.
- The largest Biogen buyer in Q1 2019 was AQR Capital Management, an estimated $335M added.
- The largest Biogen seller in Q1 2019 was Ameriprise, an estimated $509M sold.
Based on aggregated 13F filings for Q1 2019.